Access MeMed BV Assay Clinical Study Collection Protocol - Infectious Adult and Pediatric Cohorts
Purpose
The purpose of the pivotal study is to collect blood specimens and clinical data from pediatric (>90 days old) and adult (≥18 years old) patients presenting with signs and symptoms suggestive of acute bacterial or viral infection. These samples will be used to establish the diagnostic performance of MeMed BV™ for differentiating bacterial from viral infection using method comparison and/or method concordance.
Conditions
- Infection, Bacterial
- Infection Viral
Eligibility
- Eligible Ages
- Between 90 Days and 89 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Over 90 days of age. - Clinical suspicion of acute bacterial or viral infection. - Temperature ≥ 37.8°C (100°F) (any body site, any measurement device, including self-reported) or tactile fever, either of them noted at least once within the last 7 days. - Current disease duration ≤ 7 days.
Exclusion Criteria
- Previously enrolled - Insufficient sample volumes obtained - For the adult and pediatric populations, < 1.2 mL serum volume - Sample handling errors - Another unrelated episode of febrile infection within the past 2 weeks - Suspicion and/or confirmed diagnosis of infectious gastroenteritis/ colitis. - ≥48 hours of oral antibiotic treatment - ≥12 hours of intravenous\intramuscular antibiotic treatment - Human Immunodeficiency Viruses (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (self-declared or known from medical records) - A proven or suspected infection on presentation with Mycobacterial (e.g., Tuberculosis, MAC), parasitic or fungal (e.g., Candida, Histoplasma, Aspergillus) pathogen - Active inflammatory disease (e.g., Inflammatory Bowel Disease [IBD], Systemic Lupus Erythematosus [SLE], Juvenile Idiopathic Arthritis [JIA], Rheumatoid Arthritis [RA], Kawasaki, other vasculitis) - Major trauma and\or burns in the last 7 days. - Major surgery in the last 7 days - Congenital immune deficiency (CID) - Acquired immune deficiency\modulation state including 1. Active malignancy treated within last 6 months 2. Current treatment with immune-suppressive or immune-modulating therapies, including without limitations: i. Administration of P.O.\IV\IM high dose steroids >1mg/kg/day prednisone (or equivalent) at some point in the past 10 days or daily continuous use of steroids > 0.25 mg/kg/day in the past 7 days ii. Monoclonal antibodies, anti-TNF agents iii. Intravenous immunoglobulin (IVIG) iv. Cyclosporine, Cyclophosphamide, Tacrolimus, Azathioprine, Methotrexate v. G/GM-CSF Interferons c. Post solid organ/bone marrow transplant patients d. Asplenia, sickle cell disease - Indwelling central venous catheter - Cystic Fibrosis - Pregnancy - self-reported or medically known - Other severe illnesses that affect life expectancy and quality of life such as: 1. Severe psychomotor retardation 2. Congenital metabolic disorder 3. End stage renal disease, advanced heart failure (NYHA 3/4), advanced COPD (GOLD 3/4)
Study Design
- Phase
- Study Type
- Observational
- Observational Model
- Case-Only
- Time Perspective
- Prospective
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
| Adult and Pediatrics | A minimum of 244 serum samples will be collected at a minimum of two (2) US locations from enrolled pediatric and adult patients presenting signs and symptoms suggestive of acute bacterial or viral infection. The number of patients enrolled is based on total volume required to run analytical comparison studies under a future testing protocol. |
|
Recruiting Locations
Massachusetts General Brigham
Boston, Massachusetts 02114
Boston, Massachusetts 02114
More Details
- Status
- Recruiting
- Sponsor
- Beckman Coulter, Inc.
Detailed Description
The objective of this study is to collect blood specimens from pediatric (>90 days old) and adult patients (≥18 years old) presenting with signs and symptoms suggestive of acute bacterial or viral infection from hospital, Emergency Department, or Urgent Care Centers for comparative testing on the Access 2 and DxI 9000 Immunoassay Analyzers.